Pioneering AI solutions and a commitment to industry-wide RBQM advancement secures CluePoints a finalist position in the 2023 SCRIP Awards

Pioneering AI solutions and a commitment to industry-wide RBQM advancement secures CluePoints a finalist position in the 2023 SCRIP Awards

RBQM leader recognized in Specialist Providers Category at Citeline’s SCRIP Awards

King of Prussia, PA  – October 12^th, 2023: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has been shortlisted as a finalist in the Best Contract Research Organization (CRO): Specialist Providers category of the 2023 Scrip Awards.

The award category is for companies that provide niche services and is judged on the quality of both their solutions and their relationships with clients. Organizations were asked to provide evidence of their achievements between June 2022 and June 2023, which CluePoints, a key player in developing thought leadership around risk-based quality management, was able to demonstrate the advancements and success it continues to achieve.

Other projects that CluePoints has undertaken in 2023 include:

• The organization and sponsoring of the annual RBQMLive conference, which brings together industry leading speakers to discuss the developments of the RBQM approach.
• CluePoints has partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) on several projects, including a global survey of more than 125 pharma, biopharma, and CROs on current RBQM adoption patterns.
• Through a Cooperative Research and Development Agreement (CRADA), the organization has also been working with the FDA to develop a data-driven approach to site inspection, prioritization and selection.

In addition, the award eligibility period witnessed the launch of a machine learning (ML) algorithm to streamline medical coding for clients, removing the need for labor-intensive synonym lists and first-line medical coders, as well as a deep learning (DL) model to automatically identifying discrepancies and anomalies in adverse event and medication data, with up to 96% precision.

François Torche, Co-Founder and Chief Product & Technology Officer of CluePoints, commented: “We are extremely proud to have been shortlisted again for this award, in recognition of all the pioneering work we do to advance the adoption of RBQM across the industry, and the high-quality innovative solutions and services we provide our customers. Looking at our fellow finalists, we truly are in esteemed company.”

The winners will be announced during an awards presentation event at The Dorchester, London, on Thursday 16th November.

For further information on CluePoints’ solutions, please visit www.cluepoints.com

-END-

About CluePoints

CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilize comprehensive statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints® is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation you now have everything you need to adhere with global regulatory guidance. The result is increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.